Breakthrough Asthma Drug AIRSUPRA Cuts Severe Attacks by Half, Transforming 50-Year-Old Treatment Approach

Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma

WILMINGTON, Del.--(BUSINESS WIRE)--May 19, 2025-

AstraZeneca’s Airsupra asthma treatment shows breakthrough results in trial

WILMINGTON, Del. – AstraZeneca has released positive full results from its Phase IIIb BATURA trial, marking a significant advancement in asthma treatment. The trial showed that Airsupra (albuterol/budesonide), used as-needed, significantly outperformed standard albuterol rescue therapy in patients with mild asthma. These findings were simultaneously published in the New England Journal of Medicine and presented at the American Thoracic Society (…

Albuterol-budesonide yields lower asthma exacerbation risk vs albuterol alone

Albuterol-budesonide (Airsupra; AstraZeneca) resulted in a 47% reduction in severe exacerbations in mild asthma vs albuterol alone.

Breakthrough Asthma Drug AIRSUPRA Cuts Severe Attacks by Half, Transforming 50-Year-Old Treatment Approach

Landmark Phase 3 trial reveals AIRSUPRA's superior efficacy vs standard therapy, showing 47% fewer severe asthma attacks. See complete clinical data.